Qaytarish

Gepatit A virusi (HAV) ga qarshi IgM antitanachalar

Kod:17009|CPT:86709|LOINC:13950-1

Sinonimlar
Болезнь Боткинавирусный гепатитжелтухаантитела к вирусу гепатита А суммарныеантитела к вирусу гепатита А IgMAntibodies to hepatitis A virus, IgMAntibody to hepatitis A virus, IgMAnti-HAV antibodies, IgMAnti-HAV, IgMHAV Ab, IgMHepatitis A virus IgM antibodyIgM class antibody to hepatitis A virus
KabiAnti-HAV, IgM

Tahlil ma'lumotlari

Tadqiqot usuli

  • Immunokimyoluminometrik analiz (ICMA)

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • If taking biotin supplements, stop for at least 72 hours before the blood draw to reduce assay interference.
  • Do not smoke during the 30 minutes prior to specimen collection.

Qanday foydalanish

Gepatit A ga qarshi IgM antitanacha testi (anti-HAV IgM; HAV IgM antibody) qon zardobida HAV ga xos IgM ni sifat jihatida aniqlash orqali o'tkir yoki yaqinda kechgan gepatit A ni tashxislashga yordam beradi. HAV ehtimoli ko'rib chiqilganda, o'tkir gepatit belgilari, yangi boshlangan sariqlik yoki sababi tushuntirilmagan transaminaza ko'tarilishi mavjud shaxslarda buyuriladi. Dastlabki ehtimollik past bo'lgan sharoitlarda soxta musbat reaktivlik ehtimoli yuqoriroq bo'lgani sababli, testni rutin skriningdan ko'ra simptomlari bor yoki epidemiologik shubha mavjud bo'lgan shaxslarga qo'llash tavsiya etiladi.

Cheklovlar

O'tkir gepatit A gepatosellyulyar shikastlanishni keltirib chiqaradi; alanin aminotransferaza (ALT) va aspartat aminotransferaza (AST) ko'rsatkichlari ko'pincha yuqori me'yor chegarasidan bir necha martaga oshadi; qon zardobidagi bilirubin ham oshishi mumkin. Serologik tasdiq HAV ga xos antitanachalarga tayanadi: IgM o'tkir yoki yaqinda kechgan infeksiyani ko'rsatadi, IgG esa rekonvalessensiya davrida paydo bo'ladi va keyinchalik saqlanib qoladi. Ushbu tahlil qon yoki plazma donorlarini skrining qilish uchun FDA tomonidan tasdiqlanmagan yoki ma'qullanmagan. Ishlash xususiyatlari immunokomprometirlangan yoki immunosupressiya qilingan bemorlar, kindik qoni, 2 yoshdan kichik bemorlar yoki kadavralardan olingan namunalar uchun belgilab qo'yilmagan.

O'lchov birligiqualitative
Referens oraliq
MinMaks
00.8
Ko'rsatmalarWorkup of a prolonged clinical course of hepatitis A (protracted HAV)

Natija og'ishlarining mumkin sabablari

Oshgan daraja

  • hiv infection
  • systemic lupus erythematosus
  • thyroiditis

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm1 mL (min 0.4 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69(5):1-38. PubMed: 32614811.

Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. PubMed: 26042815.

Balayan MS, Zamyatina NA. Viral hepatitis A and E. In: Pokrovsky VI, Onishchenko GG, Cherkassky BL, eds. Evolution of Infectious Diseases in Russia in the 20th Century. Moscow: Meditsina; 2003:51-63.

Ryan KJ, Ray CG, eds. Sherris Medical Microbiology. 4th ed. New York: McGraw-Hill; 2004:541-544. ISBN: 0838585299.

Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th ed. Elsevier Mosby; 2005.

Musana KA, Yale SH, Abdulkarim AS. Tests of liver injury. Clin Med Res. 2004;2(2):129-131. doi:10.3121/cmr.2.2.129. PMID: 15931347.